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Background: Bacteria are frequently cultured from sputum samples of severe asthma patients suggesting a defect
in bacterial clearance from the airway. We measured the capacity of macrophages from patients with asthma to
phagocytose bacteria.
Methods: Phagocytosis of fluorescently-labelled polystyrene beads, Haemophilus influenzae or Staphylococcus aureus
by broncholaveolar lavage alveolar macrophages (AM) and by monocyte-derived macrophages (MDM) from
non-asthmatics, mild-moderate and severe asthmatic patients was assessed using fluorimetry.
Results: There were no differences in phagocytosis of polystyrene beads by AMs or MDMs from any of the subject
groups. There was reduced phagocytosis of Haemophilus influenzae and Staphylococcus aureus in MDMs from
patients with severe asthma compared to non-severe asthma (p < 0.05 and p < 0.01, respectively) and healthy
subjects (p < 0.01and p < 0.001, respectively). Phagocytosis of Haemophilus influenzae and Staphylococcus aureus by
AM was also reduced in severe asthma compared to normal subjects (p < 0.05). Dexamethasone and formoterol did
not suppress phagocytosis of bacteria by MDMs from any of the groups.
Conclusions: Persistence of bacteria in the lower airways may result partly from a reduced phagocytic capacity of
macrophages for bacteria. This may contribute to increased exacerbations, airway colonization and persistence of
inflammation.
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Patients with asthma are usually well-controlled with inhaled
corticosteroids (CS) and long-acting β2-agonists, but a
proportion of patients, described as severe asthmatics,
continue to experience uncontrolled asthma in spite of
these treatments [1]. These patients consume a significant
proportion of medical resources in terms of pharmaco-
logical treatments, hospital admissions or use of emergency
services, and time off work or school [2]. Respiratory infec-
tions are often associated with wheezing episodes and may
also impact on the development and severity of asthma.
Viral and bacterial infections or colonization with bacteria
could lead to chronic lower airway inflammation, impaired* Correspondence: p.bhavsar@imperial.ac.uk
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unless otherwise stated.mucociliary clearance, increased mucus production and
worsening of asthma [3,4]. Both viral and bacterial infec-
tions have been recognized as drivers of asthma exacerba-
tions [5]. Various bacterial species have been cultured
from sputum samples of patients during exacerbations [6],
and also during a stable period in moderate-to-severe
asthma patients [7,8]. Gram-positive Staphylococcus aur-
eus and Gram-negative Haemophilus influenzae were two
of the most common bacterial species cultured from in-
duced sputum of patients with severe asthma [8]. The
more sensitive technique of 16S ribosomal RNA micro-
array to detect bacterial species in the lower airways has
revealed an increase in bacterial burden and diversity in
patients with mild-to-moderate asthma compared to non-
asthmatic individuals [9,10]. Thus, there appears to be an
increased propensity for asthmatic subjects to carry more
bacterial pathogens in their lower airways.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tors that are vital for immune and inflammatory responses
in their response with external agents. Macrophages are
also important for the removal of particulates and bacteria
from the airways [11]. This removal of potentially patho-
genic micro-organisms via phagocytosis is essential for
maintaining a non-pathogenic environment within the
lung. However, the phagocytic capacity of macrophages
for bacteria may be impaired in various pulmonary con-
ditions. Thus, lung macrophages from children with se-
vere asthma showed reduced phagocytic responses to
Staphylococcus aureus [12]. Similarly, defective efferocytosis
by AMs from severe asthmatics but not from mild-
moderate asthmatics has also been reported [13]. This
defect has been postulated to underlie the chronic in-
flammatory state due to the accumulation of bacteria
and apoptotic and necrotic cells in the airways. In chronic
obstructive pulmonary disease (COPD), a number of stud-
ies have shown defects in both bacterial clearance [14,15]
and efferocytosis [16] indicating impaired macrophage in-
nate responses.
We hypothesize that alveolar macrophages (AMs) and
macrophages derived from blood monocytes (MDMs)
from subjects with asthma may show impaired phagocyt-
osis of Haemophilus influenzae and Staphlycoccus aureus
when compared to non-asthmatic subjects. In addition,
we examined the potential effects of the asthma treat-




Patients with asthma were recruited from the Asthma
Clinic of the Royal Brompton Hospital, London. All pa-
tients demonstrated either an improvement in FEV1
of >12% baseline FEV1 after inhaling 400 μg salbutamol
aerosol or bronchial hyper-responsiveness defined by a
concentration of methacholine provoking a fall in FEV1
of 20% or more (PC20) of <8 mg/ml. Current and ex-
smokers of >5 pack-years were excluded. Patients on
steroid-sparing agents such as methotrexate, those with
a concurrent diagnosis of clinical bronchiectasis or with
a respiratory tract infection requiring antibiotic treat-
ment within 6 weeks of enrolment were excluded.
Severe asthmatics were defined according to the American
Thoracic Society’s major criteria of needing either continuous
or near-continuous oral corticosteroids or high dose inhaled
corticosteroids (2,000 μg beclomethasone-equivalent per
day or more) or both in order to achieve a level of mild-
moderate persistent asthma, and also by the presence of 2
or more minor criteria of asthma control [17]. Patients
with non-severe asthma were those who did not fall into
the severe asthma category and who used up to 1000 μg
inhaled beclomethasone or equivalent dosage per day withwell-controlled asthma. Healthy volunteers with no diag-
nosis of asthma and with a negative PC20 (>16 mg/ml)
were also recruited. The study protocol was approved by
the Ethics Committee of Royal Brompton & Harefield
NHS Trust/National Heart & Lung Institute, London UK.
All volunteers gave their written informed consent.
Monocyte isolation and MDM differentiation
Peripheral blood mononuclear cells (PBMCs) were isolated
from 80 ml venous blood using Ficoll-Hypaque-Plus.
PBMCs and re-suspended in MDM complete media
(RPMI-1640 supplemented with 10% (v/v) FCS, 100 U/ml
penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine),
at 1 × 106 cells/ml and seeded on 96-well black plates
(105 cells/well) for 2 h at 37°C, 5% (v/v) CO2 to allow
monocytes to adhere to the plate. Non-adherent cells
were aspirated and monocytes were incubated with fresh
complete media containing GM-CSF (2 ng/ml; R&D Sys-
tems, Abingdon, UK). Monocytes were incubated at 37°C,
5% (v/v) CO2 for 12 days to allow full differentiation into
MDMs; fresh media containing GM-CSF were replenished
on days 4 and 7 [15,18,19].
Fibreoptic bronchoscopy and alveolar macrophage
isolation
Fibreoptic bronchoscopy was performed using topical
anaesthesia with lignocaine to the upper and lower air-
ways under conscious sedation with intravenous midazo-
lam. Warmed 0.9% (w/v) NaCl solution (50 ml × 4) was
instilled into the right middle lobe and bronchoalveolar
lavage (BAL) fluid was recovered by gentle hand suction.
BAL fluid was centrifuged (400 g for 10 min) and the re-
sultant cell pellet washed with Hanks’ balanced salt solu-
tion (HBSS). Cells were then suspended in culture media
(RPMI-1640, containing 10% (v/v) foetal calf serum (FCS),
100U/ml penicillin, 100 μg/ml streptomycin, 2.5 μg/ml
amphotericin, 2 mM L-glutamine). Cytospins were pre-
pared and stained with Diff Quick stain (Harleco,
Gibbstown, NJ, USA) for differential cell counts. Alveo-
lar macrophages (AMs) were purified by adhesion to the
plastic well for 4 h and then cultured overnight prior to
experimentation.
Phagocytosis assay
Phagocytosis was measured as described previously [15].
AMs and MDMs were exposed, for 4 h, to fluorescently-
labelled polystyrene beads (2 μM diameter) at a concen-
tration of 50 × 106 beads/ml or to heat-killed non-typeable
H. influenzae or to S. aureus, all labelled with Alexa-Fluor
488 conjugate (Invitrogen, Paisley, Scotland). AMs and
MDMs were washed with Dulbecco-phosphate buffered
saline and extracellular fluorescence was quenched with
1% (w/v) trypan blue at room-temperature. Trypan blue
was aspirated and phagocytosis of fluorescent-labeled
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a Fluostar Optima fluorimeter (BMG LabTech, Aylesbury,
Buckinghamshire) at excitation wavelength of 480 nm and
emission wavelength of 520 nm. Data were expressed as
relative fluorescent units (RFU). In order to determine
that the beads or bacteria were being internalised, cells
were exposed to cytochalasin D (5 μg/ml) for 30 min,
prior to incubation with bacteria.
Confocal microscopy was used to visualize whether the
beads or bacteria were internalised. MDM (2×105cells)
were cultured on well Lab-tek Permanox chamber slides
and phagocytosis performed as described above. Cells
were then incubated at 37°C in 5% (v/v) CO2 with Cell-
Tracker Red CMPTX dye (12.5 μM; Invitrogen, Paisley,
Scotland) for 45 min to stain the cytoplasm. Cells were
then fixed with 4% (w/v) paraformaldehyde. The nuclei were
stained by incubation with 4’6-diamidino- 2-phenylindole
dihydrochloride (DAPI; 250 μM) for 3 min. Cells were
viewed on a confocal microscope with Krypton-Argon
laser fluorescence detector.Cell viability
Cell viability, as determined by metabolic activity, was per-
formed using an MTT (3-(4,5-dimethylthiazol-2-yl)- 2,
5-diphenyltetrazolium bromide) assay.Data analysis
Results are expressed as mean ± SEM. A Kruskal-Wallis
test or Dunnett's test was used for multi-group com-
parisons as appropriate. Differences between the effects of
dexamethasone or formoterol or dexamethasone and for-
moterol treatment were analysed using Wilcoxon paired
t-test. A Mann-Whitney test was also used where appro-
priate. Correlations were determined using Spearman rank
correlation coefficient. A p value of <0.05 was considered




Age (years) 39.6 ± 2.7
Atopy# 2/14
Duration of asthma (years) 0
Exacerbations in past year 0
FEV1 (% predicted) 98.31 ± 3.28
FVC (% predicted) 97.00 ± 3.16
Oral prednisolone (mg/d) 0
Inhaled cortico-steroid, BDP equivalent (μg/day) 0
Abbreviations: BDP Beclomethasone dipropionate, FEV1 forced expiratory volume in
#Atopy defined as positive skin prick test to one or more aeroallergens.
Data shown as mean ± SEM. **p < 0.01, ***p < 0.001 compared to non-severe asthmResults
Participant characteristics
Severe asthmatics had lower FEV1 (% predicted) and
FVC (% predicted) compared to both non-severe asth-
matics and normal subjects (Table 1). They were also on
higher doses of inhaled corticosteroids and reported a
greater frequency of exacerbations. Of 14 patients with
severe asthma recruited to the MDM study (Table 1), 10
were on daily oral prednisolone. In the severe asthmatics
recruited to the AM study (Table 2), there was a trend
towards higher eosinophil and neutrophils counts in
BAL compared to both healthy and non-severe asth-
matic subjects. Three subjects had studies performed on
AMs and MDMs.
Phagocytosis by MDMs
Having established the assay conditions, MDMs from
normal subjects and patients with non-severe and severe
asthma were exposed to fluorescently-labeled beads or
bacteria. There was no difference in phagocytosis of
beads between the groups (Figure 1A). However, there
was impaired phagocytosis of fluorescently-labelled H.
influenzae by MDMs from severe asthmatics compared
to cells from non-severe asthmatic patients (p < 0.05)
and normal subjects (p < 0.01; Figure 1B). MDM phago-
cytosis of fluorescently-labelled S. aureus was also im-
paired in severe asthma compared to non-severe asthma
(p < 0.01) and normal subjects (p < 0.001). There was no
difference in the ability of MDMs from non-severe asth-
matics to phagocytose either bacterial species compared
to normal subjects.
Phagocytosis by alveolar macrophages
AMs from all subject groups had a similar capacity to
phagocytose beads (Figure 2A). AMs from severe asthmatic
patients exhibited a reduced capacity to phagocytose bac-
teria similar to that observed in MDMs (Figure 2B, 2C).ophage study
Non-severe asthma Severe asthma
14 14
8:6 9:5
45.9 ± 3.6 48.6 ± 2.9
10/14 14/14
33.1 ± 4.0 37.9 ± 4.6
1.57 ± 0.48 3.78 ± 0.26***
83.40 ± 3.41 68.24 ± 4.29**
95.51 ± 3.70 81.99 ± 2.65**
0 14.50 ± 3.0*** (n = 10)
971 ± 203 (n = 11) 2257 ± 321** (n = 14)
1 sec, F Female, FVC forced vital capacity, M Male.
a.
Table 2 Characteristics of subjects in the alveolar macrophage study
Normal Non-severe asthma Severe asthma
n 7 6 8
Sex (F:M) 2:5 3:3 5:3
Age (years) 39 ± 5.6 34.7 ± 6.0 43.75 ± 29
Atopy# 1/7 6/6 6/8
Duration of asthma (years) 0 25.2 ± 5.9 35.8 ± 5.2
Exacerbation in past year 0 0.33 ± 0.33 3.25 ± 0.41***
FEV1 (% predicted) 94.71 ± 15.7 83.08 ± 4.25 79.69 ± 4.95
FVC (% predicted) 95.27 ± 14.65 97.43 ± 7.55 89.11 ± 4.35
Oral prednisolone (mg/day) 0 0 8.13 ± 4.8 (n = 3)
Inhaled corticosteroid BDP equivalent (μg/day) 0 600 ± 263 2200 ± 414*
Total BAL count (×106) 10.7 ± 3.8 8.67 ± 3 7.3 ± 1.9
Cells/ml (×103) 85 ± 24.4 74 ± 24.3 63.8 ± 18.9
Lymphocyte (%) 18.6 ± 7 7.9 ± 1.4 5.12 ± 1.6
Eosinophil (%) 0.6 ± 0.2 2.04 ± 1.2 4.14 ± 2.4
Macrophage (%) 76.6 ± 7.7 88.2 ± 1.7 84.6 ± 12.4
Neutrophil (%) 2.97 ± 1.2 1.37 ± 0.4 5.6 ± 2
Abbreviations: BAL Bronchoalveolar lavage, BDP Beclomethasone dipropionate, F Female, FEV1 forced expiratory volume in 1 sec, FVC forced vital capacity, M male.
#Atopy defined as positive skin prick test to one or more common aeroallergens.
Data shown as mean ± SEM. *p < 0.05, ***p < 0.001 compared to non-severe asthma.
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H. influenzae in severe asthma compared to normal sub-
jects (Figure 2B; p < 0.05 (Kruskal-Wallis, post-hoc test));
for S. aureus, this impairment did not reach significance.
However, there was a significant difference between the
phagocytic response to S. aureus when healthy subjects
were directly compared to severe asthmatics (p < 0.01;
Mann-Whitney).
Phagocytosis, FEV1 and eosinophilia
Phagocytosis by MDMs of both H. influenzae (r = 0.48,
p = 0.001, Figure 3A) and S. aureus (r = 0.40, p = 0.019,
Figure 3B) correlated with FEV1 (% predicted). Phagocyt-
osis by AMs of H. influenzae did not significantly correl-
ate with FEV1 (% predicted) (r = 0.4, p = 0.06, Figure 3C)
but phagocytosis of S. aureus (r = 0.50, p = 0.036, Figure 3D)
did positively correlate with FEV1 (% predicted). For both
MDMs and AMs, neither FEV1/FVC ratio nor age corre-
lated with any of the phagocytic responses (data not
shown). For AMs, there was an inverse correlation be-
tween the phagocytic response to S. aureus (but not to
H. influenzae) and the % eosinophil in BAL fluid (r = -0.57;
p < 0.01; Additional file 1: Figure S2).
Internalisation of S. aureus by MDM
Confocal microscopy was used to confirm that particles
and bacteria were being internalized (Figure 4) and
showed uptake of both beads and S. aureus within
MDMs (Figure 4A and B). In order to further confirm
the process of internalization, MDMs were exposed tocytochalasin D (5 μg/ml), an inhibitor of actin filament
polymerization, prior to incubation with S. aureus
(Figure 4C). This led to an inhibition of phagocytosis
with S. aureus unable to enter the cells, localizing to the
outer cell membrane of MDMs. Having established that
cytochalasin D prevented phagocytosis, we determined
whether the fluorimetric plate reader assay could distin-
guish between intra-cellular bacteria (phagocytosis) and
outer membrane-associated bacteria. Phagocytosis experi-
ments were then performed in the absence and presence
of cytochalasin D. Phagocytosis of beads, H. influenzae
and S. aureus was suppressed in MDMs from all patient
groups as indicated by the difference in fluorescence units
(Figure 4D-F). There was a significant difference for all
groups and particles between non- stimulated and Cyto D
treated cells (Figure 4D-F).
Effect of dexamethasone on phagocytosis
In order to investigate whether corticosteroids could in-
fluence the phagocytic response, MDMs isolated from
normal subjects, and non-severe and asthmatics were
exposed to dexamethasone prior to addition of beads or
bacteria. Dexamethasone improved phagocytosis of beads
and bacteria by MDM from normal subjects and non-
severe asthmatics to a small extent (~10%) at low concen-
trations, reaching significance at 10-8 M, and also at 10-7 M
for beads only, but this effect was not seen at higher con-
centrations of dexamethasone (Figure 5). Dexamethasone
did not change the phagocytic response of MDMs obtained
from patients with severe asthma. Dexamethasone did not
Figure 1 Phagocytosis of fluorescently-labelled beads (Panel A),
H. influenzae (Panel B) or S. aureus (Panel C) by monocyte-derived
macrophages (MDM). MDM were obtained from normal subjects
(●, n = 14) and patients with non-severe asthma (NSA; ■, n = 14) or
severe asthma (SA;▲, n = 14). Phagocytosis was reported as relative
fluorescence unit (RFU). Data are presented as dot plots and medians.
A Kruskal-Wallis test followed by Dunnett's post-hoc test was used for










































Figure 2 Phagocytosis of beads, H. influenzae or S. aureus by
alveolar macrophages. Alveolar macrophages from normal subjects
(●, n = 7) and patients with non-severe asthma (NSA; ■, n = 6) or
severe asthma (SA; ▲, n = 8) were obtained by bronchoalveolar
lavage. Alveolar macrophages were exposed to fluorescently-labeled
beads (Panel A) or H. influenzae or S. aureus (Panels B and C) for
4 h and phagocytosis reported as relative fluorescence units (RFU).
Data are presented as dot-plots and medians. A Kruskal-Wallis test
by Dunnett's post-hoc test was used for multi-group comparisons
where *p < 0.05. Direct comparison between normal subjects and
SA for S.aureus (C) was performed using a Mann-Whitney t-test
where $p < 0.01.
Liang et al. Respiratory Research 2014, 15:72 Page 5 of 11
http://respiratory-research.com/content/15/1/72
Figure 3 Relationship between phagocytosis and lung function parameters. MDM were derived from normal subjects (●, n = 14),
non-severe (■, n = 14) and severe asthmatics (▲, n = 14) and exposed to either fluorescently-labeled H. influenzae (Panel A) or S. aureus (Panel B).
Alveolar macrophages from normal subjects (●, n = 7) and patients with non-severe asthma (NSA; ■, n = 6) or severe asthma (SA;▲, n = 8) were
exposed to either fluorescently-labeled H. influenzae (Panel C) or S. aureus (Panel D). Correlations were determined using Spearman rank
correlation coefficient.
Liang et al. Respiratory Research 2014, 15:72 Page 6 of 11
http://respiratory-research.com/content/15/1/72affect cell metabolic activity as measured by MTT assay
(Additional file 1: Figure S1A).
Effect of formoterol alone or in combination with
dexamethasone
The effect of the long-acting inhaled β2-agonist, formoterol,
and the combination of dexamethasone and formoterol on
phagocytosis of MDMs was investigated. Formoterol alone
had no effect on phagocytosis of bacteria by MDMs in any
of the subject groups (Figure 6A-B). The combination of
formoterol with dexamethasone at 10-8 M each caused a
small improvement of phagocytosis of H. influenzae by
MDMs from normal subjects and non-severe asthmatics
(p < 0.05, Figure 6C), but this was not seen in MDMs from
severe asthmatic subjects (Figure 6C and 6D). Forphagocytosis of S. aureus by MDMs, there was also an
improvement with dexamethasone and formoterol at
10-8 M for normal individuals (p < 0.01, Figure 6D) and
for non-severe asthmatics with dexamethasone and for-
moterol at 10-8 and 10-9 M (p < 0.05, Figure 6D). Formo-
terol did not affect cell metabolic activity as measured
by MTT assay (Additional file 1: Figure S1B).
Discussion
We investigated whether macrophage clearance of bacter-
ial species associated with asthmatic airways were altered
in asthma. We showed that there was a reduction in
phagocytosis of fluorescently-labelled H. influenzae and
S. aureus by MDMs from patients with severe asthma
compared with MDMs from healthy controls; however
Beads








































































A B  C
Figure 4 Confocal microscopy of fluorescently-labeled beads or bacteria by MDM and effect of cytochalasin D. Panels A-C: MDM were
derived from a patient with non-severe asthma and exposed to either fluorescently-labelled beads (Panel A) or S. aureus for 4 h (green) (Panel B).
Panel C shows lack of phagocytosis of S.aureus in the presence of cytochalasin D. Cell cytoplasm was stained with Cell Tracker Red and the nuclei with
DAPI (blue). Panels D-F: MDMs were derived from normal subjects (●), non-severe asthmatics (NSA; ■) or severe asthmatics (SA;▲) and pretreated
with cytochalasin D (cyto D; 5 μg/ml) prior to incubation with beads (Panel D), H. i influenzae (Panel E) or S. aureus (Panel F) for 4 h. Phagocytosis
was measured by fluorimetry and reported as relative fluorescence units (RFU). NS = not stimulated. A paired t-test was used to determine the effect of
Cytochalasin D on phagocytosis. **p < 0.01, ***p < 0.001.
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asthmatics. We also showed that alveolar macrophages
from severe asthma patients exhibited compromised
phagocytic capacities for these bacterial species. How-
ever, the phagocytic response of these macrophages and
MDMs to polystyrene beads was not altered in cells
from patients with asthma, indicating that the defect
was related specifically to these bacteria. These results
are an extension of previous observations in children,
where phagocytosis of inactivated S. aureus was im-
paired in alveolar macrophages from patients with se-
vere asthma and to a lesser extent in those with
moderate asthma [12]. This observation may underlie
the increased risk of bacterial infections that has been
described in patients with stable severe asthma [8,20].
In addition, this defect in bacterial phagocytosis may ex-
plain partly the presence of the altered microbiome that
has been described in the airways of patients with asthma
compared with healthy subjects [9]. A similar defect in thephagocytosis of bacterial pathogens by MDMs and AMs
from patients with COPD has also been reported [15], also
in association with an altered microbiome in the airways
of patients with COPD [9,21].
MDMs and macrophages obtained from non-severe
asthmatic patients did not show reduced phagocytosis of
H. influenzae and S. aureus compared to normal sub-
jects suggesting that the phagocytic defect was associ-
ated with more severe asthma. Severe asthma exhibits a
number of similarities with COPD such as the presence
of airway neutrophilia [22]. Our results are in line with a
recent study showing that macrophages isolated from in-
duced sputum from asthmatic subjects with increased
neutrophil counts in the sputum were also less able to
phagocytose apoptotic bronchial epithelial cells [23], in-
dicating a defect in the process of efferocytosis in the
airways of patients with asthma. The defect in phagocyt-
osis of bacteria could lead to a persistence of airway bac-
teria resulting in airway neutrophilia through the release
Figure 5 Effect of dexamethasone on phagocytosis by MDM.
MDM from normal subjects (●, n = 14), non-severe asthmatics (■, n = 14)
and severe asthmatics (▲, n = 14) were pre-treated with dexamethasone
for 1 h prior to exposure to fluorescently-labelled beads (Panel A),
H. influenzae (Panel B) or S.aureus (Panel C) for 4 h. Phagocytosis
was measured by fluorimetry and presented as mean ± SEM. A
Mann-Whitney test was used to compare the effect of given concentration
of dexamethasone with that of untreated samples. **p < 0.01 and
***p < 0.001 compared to untreated cells.
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to worsening of asthma in terms of severity of symptoms
and recurrence of exacerbations. Recent work has indi-
cated that in-vitro infection of lung tissue macrophages
with rhinovirus resulted in an impairment of the phago-
cytosis of bacteria by alveolar macrophages [24]. This
mechanism of defective bacterial phagocytosis by the pres-
ence of rhinovirus may be relevant to acute severe asthma,
where a high percentage of positive bacterial cultures from
sputum samples has also been reported [25].
The cellular and molecular mechanisms for this phago-
cytic defect of macrophages from patients with severe
asthma are unclear. Macrophages are important for both
innate and acquired immunity in the respiratory tract, and
have a pivotal role in lung defense against viruses, bacteria
and fungi [26]. The findings of this study indicate that, in
severe asthma, an impairment of the ability of alveolar
macrophages to phagocytose bacteria could lead to pro-
longed persistence of bacteria in the airways and lungs,
which could contribute to the worsening of asthma con-
trol. In a previous study, we showed that the release of
pro-inflammatory cytokines from peripheral blood mono-
nuclear cells and alveolar macrophages from patients with
asthma, stimulated with lipopolysacharide, was not differ-
ent from that of patients with non-severe asthma [27,28],
indicating that the inflammatory response to one constitu-
ent of gram-negative bacteria is not impaired in severe
asthma. However, the response of these cells to whole bac-
teria is not known. Reactive oxygen species production by
alveolar macrophages is required for bacterial killing [29],
and is also important for phagocytosis. In mice lacking the
antioxidant enzyme extracellular superoxide dismutase
[30], macrophage phagocytosis of bacteria was impaired,
suggesting that removal of reactive oxygen species within
alveolar macrophages is required for normal phagocytosis.
There was a positive correlation between airflow ob-
struction as measured by FEV1 and phagocytosis of bac-
teria, either S. aureus or H. influenzae, by alveolar
macrophages and MDMs. The link between the reduced
bacterial phagocytosis and airflow obstruction remains un-
clear. Airflow obstruction in severe asthma has been asso-
ciated with eosinophilic inflammation, duration of asthma
and thickening of the airways as measured by high reso-


















































































Figure 6 Effect of formoterol alone or in combination with dexamethasone on phagocytosis. MDM were derived from from normal
subjects (●, n = 5), non-severe asthmatics (■, n = 6) and severe asthmatics (▲, n = 5) were pre-treated with formoterol in the absence or presence
of dexamethasone for 1 h prior to exposure to H. influenzae (Panels A and C) or S. aureus (Panels B and D) for 4 h. Phagocytosis was measured
by fluorimetry and data presented as mean ± SEM. Differences between the effects of dexamethasone or formoterol or dexamethasone and
formoterol treatment were analysed using Wilcoxon paired t-test, where *p < 0.05 and **p < 0.01 compared to untreated cells. D = dexamethasone,
F = formoterol.
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been associated with the presence of chronic airflow ob-
struction. The negative correlation between the percent-
age of eosinophils in bronchoalveolar lavage fluid and
the phagocytic response to S. aureus of macrophages from
asthma patients also support a potential role for eosino-
philic inflammation. Eosinophlic inflammation is an im-
portant source of oxidative stress in asthma [31], and
oxidative stress has been linked to defective phagocyt-
osis of bacteria [32].
Inhaled corticosteroids and β-agonists remain the main-
stay of treatment of many patients with asthma [33]. Pa-
tients with more severe asthma are usually treated with
high doses of these agents. In addition, the majority of the
patients with severe asthma in our study were also on oral
corticosteroid therapy. However, many patients with se-
vere asthma may not achieve control and this lack of
therapeutic response to corticosteroids has been attributed
to the development of corticosteroid insensitivity [27,28].
Oxidative stress pathways [34] and activation of mitogen-
activated protein kinases have been implicated as mech-
anisms of corticosteroid insensitivity in severe asthma
[27,35]. Bacterial interactions with epithelial cells andmacrophages can activate these pathways and therefore
could underlie corticosteroid insensitivity.
Neither dexamethasone nor formoterol had any dele-
terious effects on the phagocytic response in MDM from
any of the subject groups. Dexamethasone alone or com-
bined with formoterol slightly improved the phagocytic
response of MDM for both beads and bacteria obtained
from healthy subjects but not from those with asthma.
The significance of this small increase is unlikely to be
clinically relevant. There was also no effect of the phago-
cytic response towards either H. influenzae or S. aureus in
severe asthma by dexamethasone or formoterol, which
contrasts to the increase in phagocytosis of bacteria by
MDMs stimulated by budesonide previously reported in
COPD patients [15]. However, in another study, budeso-
nide decreased phagocytosis in alveolar macrophages from
healthy never-smoked subjects by decreasing the number
of cells with the ability to phagocytose as well as decreas-
ing phagocytic capacity of these cells [36]. These short-
term studies will not categorically exclude the possibility
that long-term usage of corticosteroids and long-acting
β-agonists in severe asthma may have a detrimental effect
on macrophage phagocytosis.
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http://respiratory-research.com/content/15/1/72A possible shortcoming of the study could be the lower
number of subjects recruited to the AM study as a result
of the inherent problems associated with collecting BAL
samples from severe asthmatics. However, these studies
performed in AM were proof of principle studies to con-
firm, ex vivo, the findings of the MDM study. Moreover,
although there are studies showing that macrolides [37]
and antifungal agents [38] can improve the phagocytic
capabilities of macrophages, our results show that in the
presence of antifungal and/or antibacterial agents, AMs
and MDMs from patients with asthma continue to display
an inherent impaired phagocytic response compared to
those from control subjects
In summary, MDMs and AMs from severe asthma pa-
tients demonstrate reduced phagocytosis of fluorescently-
labelled H. influenzae and S. aureus. This may contribute
to the bacterial colonisation of the lower airways and to
the propensity for bacterial exacerbations in severe
asthma. This defect is unlikely to result from an acute
response to corticosteroid or β-adrenergic therapy. Fur-
ther work is needed to determine the cellular and mo-
lecular basis of this phagocytic defect for bacteria.
Conclusions
Persistence of bacteria in the lower airways may result
partly from a reduced phagocytic capacity of macrophages
for bacteria. This may contribute to increased exacerba-
tions, airway colonization and persistence of inflammation.
Additional file
Additional file 1: Figure S1. Effect of dexamethasone or formoterol on
metabolic activity of MDM. MDM from normal subjects, non-severe
asthmatics and severe asthmatics were treated with dexamethasone (A)
or formoterol (B) for 1h and cells assayed for metabolic activity using
MTT assay. Figure S2. Relationship between phagocytosis of S. aureus by
AM and % eosinophils in BAL. Alveolar macrophages from normal
subjects (●, n = 7) and patients with non-severe asthma (■, n = 6) or
severe asthma (▲, n = 8) were exposed to fluorescently-labelled S. aureus.
Correlations were determined using Spearman’s rank correlation coefficient.
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